Novartis' heart failure med Entresto wins FDA panel backing for bigger patient group—but just how much bigger?

Novartis' heart failure med Entresto wins FDA panel backing for bigger patient group—but just how much bigger?

Source: 
Fierce Pharma
snippet: 

Novartis now looks almost certain to pocket an important first-in-class approval for blockbuster heart drug Entresto, despite trial data that, at least on the surface, spelled failure for the drug.

An FDA advisory panel voted 12-1 for Entresto’s use in heart failure patients with preserved ejection fraction (HFpEF), a group whose hearts are compromised but haven’t yet lost as much power as those now approved for Entresto treatment.